BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30217568)

  • 1. Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.
    Russo JW; Liu X; Ye H; Calagua C; Chen S; Voznesensky O; Condulis J; Ma F; Taplin ME; Einstein DJ; Balk SP; Chen S
    Cancer Lett; 2018 Dec; 438():97-104. PubMed ID: 30217568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer.
    Gao X; Liang J; Wang L; Zhang Z; Yuan P; Wang J; Gao Y; Ma F; Calagua C; Ye H; Voznesensky O; Wang S; Wang T; Liu J; Chen S; Liu X
    Mol Oncol; 2021 Jul; 15(7):1901-1920. PubMed ID: 33932081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.
    Knuuttila M; Mehmood A; Huhtaniemi R; Yatkin E; Häkkinen MR; Oksala R; Laajala TD; Ryberg H; Handelsman DJ; Aittokallio T; Auriola S; Ohlsson C; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
    Am J Pathol; 2018 Jan; 188(1):216-228. PubMed ID: 29126837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
    J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
    Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
    Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
    Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.
    Wang J; Zou JX; Xue X; Cai D; Zhang Y; Duan Z; Xiang Q; Yang JC; Louie MC; Borowsky AD; Gao AC; Evans CP; Lam KS; Xu J; Kung HJ; Evans RM; Xu Y; Chen HW
    Nat Med; 2016 May; 22(5):488-96. PubMed ID: 27019329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
    Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.